NDA 205435 · Cubist Pharms LLC
Sivextro
Tedizolid Phosphate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jun 20, 2014
Approved uses
4
Original approval plus efficacy supplements
Registered trials
35
7 Phase 3, 2 recruiting
FAERS reports
803
528 serious, 51 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 27, 2026.
SIVEXTRO is an oxazolidinone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible microorganisms in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg) ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Acute Bacterial Skin and Skin Structure Infections SIVEXTRO ® is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus Group (including Streptococcus anginosus , Streptococcus intermedius , and Streptococcus constellatus ), and Enterococcus faecalis , in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg). 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric...
Mechanism: Tedizolid is an antibacterial drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 4, 2025 Supplement 16 · Efficacy LabelLetter
- Jun 19, 2020 Supplement 12 · Efficacy LetterLabel
- Mar 6, 2019 Supplement 10 · Efficacy LabelLetter
- Jun 20, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelSummary ReviewReview
1 products under this application
- SIVEXTRO · TEDIZOLID PHOSPHATE 200MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tedizolid" as an intervention, any sponsor and status, largest first.
- Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)Pivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT02019420 · 726 participants · Start Jan 6, 2014 · Primary completion Jun 22, 2018
Drug: Tedizolid phosphate; Linezolid · For: Pneumonia
- TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.Pivotal-lookingCompleted
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT01170221 · 667 participants · Start Aug 15, 2010 · Primary completion Sep 30, 2011
Drug: TR-701 FA; Linezolid · For: Skin and Subcutaneous Tissue Bacterial Infections
Sites: Dothan, Alabama; Anaheim, California; Buena Park, California · 84 sites in all
- TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT01421511 · 666 participants · Start Sep 15, 2011 · Primary completion Jan 10, 2013
Drug: TR-701 FA; Linezolid · For: Skin and Subcutaneous Tissue Bacterial Infections
Sites: Dothan, Alabama; Chula Vista, California; Escondido, California · 117 sites in all
- Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02066402 · 598 participants · Start Mar 4, 2014 · Primary completion Mar 6, 2016
Drug: Tedizolid (BAY119-2631); Placebo Tedizolid (BAY119-2631) and 2 more · For: Bacterial Infections
Sites: Chula Vista, California; La Mesa, California; Oceanside, California · 55 sites in all
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective EndocarditisPivotal-lookingRecruiting
Fundacion Clinic per a la Recerca BiomédicaAcademic, hospital or other
NCT05398679 · 360 participants (planned) · Start Aug 17, 2022 · Primary completion Dec 30, 2026
Drug: Cefaclor; Ciprofloxacin Tablets and 22 more · For: Endocarditis Infective
Sites: Alicante, Spain; Seville, Spain; Palma de Mallorca, Spain · 20 sites in all
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT01519778 · 200 participants · Start Feb 15, 2012 · Primary completion Aug 27, 2012
Drug: TR701 FA · For: Major Cutaneous Abscess; Cellulitis; Erysipelas
Sites: Anaheim, California; Buena Park, California; Chula Vista, California · 10 sites in all
- Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure InfectionsPivotal-lookingCompleted
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00761215 · 192 participants · Start Sep 17, 2008 · Primary completion Feb 24, 2009
Drug: TR-701 200 mg; TR-701 300 mg and 1 more · For: Skin Diseases, Infectious; Skin Diseases, Bacterial
Sites: Dothan, Alabama; Chula Vista, California; Long Beach, California · 12 sites in all
- Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) InfectionsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01967225 · 125 participants · Start Nov 23, 2013 · Primary completion Oct 28, 2016
Drug: Tedizolid Phosphate (Sivextro, BAY1192631); Linezolid · For: Skin Diseases, Infectious
Sites: Nagakute, Japan; Nagoya, Japan; Toyoake, Japan · 46 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use110
- product use in unapproved indication88
- thrombocytopenia62
- anaemia51
- nausea45
- no adverse event43
- drug ineffective36
- pancytopenia34
- product availability issue33
- product dose omission issue32
- diarrhoea27
- rash25
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 10 |
| 2015 | 39 |
| 2016 | 34 |
| 2017 | 41 |
| 2018 | 55 |
| 2019 | 108 |
| 2020 | 83 |
| 2021 | 73 |
| 2022 | 62 |
| 2023 | 109 |
| 2024 | 69 |
| 2025 | 72 |
| 2026 | 48 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sivextro* (Tedizolid Phosphate)
2024 spending
$16.5M
Beneficiaries
505
1,534 claims
Per beneficiary
$32,723
$421.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,709,902 |
| 2021 | $12,823,638 |
| 2022 | $17,779,287 |
| 2023 | $11,498,831 |
| 2024 | $16,525,191 |
Part B: Sivextro (Tedizolid Phosphate) · HCPCS J3090
2024 spending
$52K
Beneficiaries
28
149 claims
Per beneficiary
$1,841
2024 ASP limit $1.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $80,337 |
| 2021 | $43,542 |
| 2022 | $72,395 |
| 2023 | $53,138 |
| 2024 | $51,551 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tedizolid for osteoarticular infections: Evaluation of the published evidence.
Athanasiou V, Ragias D, Tzikopoulou M, et al. · Eur J Pharmacol 2025 · Systematic Review
- Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.
Flanagan S, Minassian SL, Passarell JA, et al. · J Clin Pharmacol 2017 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
McCool R, Gould IM, Eales J, et al. · BMC Infect Dis 2017 · Systematic Review, Network Meta-Analysis
- Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
Flanagan SD, Minassian SL, Prokocimer P · Clin Pharmacol Drug Dev 2018 · Clinical Trial, Phase I, Comparative Study
- Comparison of digital planimetry and ruler technique to measure ABSSSI lesion sizes in the ESTABLISH-1 study.
Bien P, De Anda C, Prokocimer P · Surg Infect (Larchmt) 2014 · Clinical Trial, Phase III, Randomized Controlled Trial
- Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant Staphylococcus aureus: A Systematic Review and Meta-Analysis.
Hasannejad-Bibalan M, Mojtahedi A, Biglari H, et al. · Microb Drug Resist 2019 · Meta-Analysis, Systematic Review
Sponsor: Cubist Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.